More on Gilead Sciences (GILD): Q3 beats across the board. Net earnings fell 8.9% Y/Y however, on higher R&D expenses to advance its liver disease and oncolodgy products. Overall product sales rose 14%, with sales of antiviral products, its dominant revenue stream, increasing 13%. HIV drugs Atripla and Truvada both saw sales gains of 9% and 8%, respectively. Royalty, contract and other revenue from collaborations were up 23% from the prior year. Shares +1.7% AH.